|
Tuesday 21st August 2018 |
Text too small? |
SeaDragon is calling on its shareholders to pay a 10 percent premium to participate in a $14.9 million pro-rata renounceable offer to help struggling fish oil manufacturer remain afloat.
The company forecast a net loss of between $3.6 million and $4.6 million in the year ending March 31, 2019, and said its ability to deliver on forecasts depends on securing long-term funding for the company.
“As previously announced to shareholders in May 2018, the company has been considering capital raising options and has decided to initiate a rights offer to shareholders to provide additional capital to facilitate growth and meet working capital, operational expenditure needs and capital expenditure items," said SeaDragon chairman Colin Groves.
The offer will be a 1-for-1 with an issue price of 3.3 cents per share, which is the same price as the conversion price under the convertible loan note agreements with cornerstone investors Pescado Holdings Ltd and One Funds Management Ltd. The shares last traded at 0.3 cents, valuing the company at $13.5 million, and have halved so far this year.
SeaDragon had already hammered out a deal under which Australian investment firm BioScience Managers and Pescado Holdings, which is associated with Christchurch's rich-lister Stewart family, each agreed to advance up to $3 million via a new convertible loan note facility. An existing convertible loan note facility and existing option to purchase $3 million of ordinary shares in SeaDragon with Comvita will be amended.
The rights offer document will be released to the market on Aug. 28 and shareholders will be able to subscribe for one new share for every share they hold as of 5pm on the Aug. 29 record date. Eligible shareholders who subscribe for their full entitlement of new shares under the offer may also apply for additional shares through an oversubscription facility.
(BusinessDesk)
No comments yet
CHI - Channel Infrastructure delivers solid FY25 financial result
February 27th Morning Report
TRU - Results Guidance FY2026
TRU - Results Guidance FY2026
MEE - Me Today announces six-month results to 31 December 2025
HGH - Heartland announces 1H2026 result
BRW - FY26 Half Year Results Announcement
February 25th Morning Report
Genesis completes NZ$100m Placement
MCY - Invests heavily in renewables; delivers strong performance